{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T16:42:09Z","timestamp":1787244129321,"version":"build-2736575974"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T00:00:00Z","timestamp":1766102400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T00:00:00Z","timestamp":1766102400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1038\/s41375-025-02842-w","type":"journal-article","created":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T07:05:57Z","timestamp":1766127957000},"page":"304-313","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["BET inhibitor-based combinations targeting novel dependencies in MECOM-rearranged (r) AML"],"prefix":"10.1038","volume":"40","author":[{"given":"Christine E.","family":"Birdwell","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7343-6214","authenticated-orcid":false,"given":"Warren","family":"Fiskus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0957-6009","authenticated-orcid":false,"given":"Christopher P.","family":"Mill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9892-9832","authenticated-orcid":false,"given":"Tapan M.","family":"Kadia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7103-373X","authenticated-orcid":false,"given":"Naval","family":"Daver","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9003-0390","authenticated-orcid":false,"given":"Courtney D.","family":"DiNardo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Sasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John A.","family":"Davis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4702-0386","authenticated-orcid":false,"given":"Kaberi","family":"Das","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1951-3522","authenticated-orcid":false,"given":"Hanxi","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antrix","family":"Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2953-6485","authenticated-orcid":false,"given":"Anna","family":"Malovannaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren B.","family":"Flores","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1175-2032","authenticated-orcid":false,"given":"Rasoul","family":"Pourebrahim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Selina","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoping","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Ceribelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5209-5126","authenticated-orcid":false,"given":"Kapil N.","family":"Bhalla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,19]]},"reference":[{"key":"2842_CR1","first-page":"2665","volume":"11","author":"AS Perkins","year":"1991","unstructured":"Perkins AS, Fishel R, Jenkins NA, Copeland NG. Evi-1, a murine zinc finger proto-oncogene, encodes a sequence-specific DNA-binding protein. Mol Cell Biol. 1991;11:2665\u201374.","journal-title":"Mol Cell Biol"},{"key":"2842_CR2","first-page":"183","volume":"12","author":"K Morishita","year":"1992","unstructured":"Morishita K, Parganas E, Matsugi T, Ihle JN. Expression of the Evi-1 zinc finger gene in 32Dc13 myeloid cells blocks granulocytic differentiation in response to granulocyte colony-stimulating factor. Mol Cell Biol. 1992;12:183\u20139.","journal-title":"Mol Cell Biol"},{"key":"2842_CR3","doi-asserted-by":"publisher","first-page":"3232","DOI":"10.1038\/sj.onc.1205436","volume":"21","author":"V Senyuk","year":"2002","unstructured":"Senyuk V, Chakraborty S, Mikhail FM, Zhao R, Chi Y, Nucifora G. The leukemia-associated transcription repressor AML1\/MDS1\/EVI1 requires CtBP to induce abnormal growth and differentiation of murine hematopoietic cells. Oncogene. 2002;21:3232\u201340.","journal-title":"Oncogene"},{"key":"2842_CR4","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.1158\/0008-5472.CAN-08-2562","volume":"69","author":"L Laricchia-Robbio","year":"2009","unstructured":"Laricchia-Robbio L, Premanand K, Rinaldi CR, Nucifora G. EVI1 Impairs myelopoiesis by deregulation of PU.1 function. Cancer Res. 2009;69:1633\u201342.","journal-title":"Cancer Res"},{"key":"2842_CR5","doi-asserted-by":"publisher","first-page":"13591","DOI":"10.1074\/jbc.M115.708156","volume":"291","author":"M Wilson","year":"2016","unstructured":"Wilson M, Tsakraklides V, Tran M, Xiao YY, Zhang Y, Perkins AS. EVI1 Interferes with Myeloid Maturation via Transcriptional Repression of Cebpa, via Binding to Two Far Downstream Regulatory Elements. J Biol Chem. 2016;291:13591\u2013607.","journal-title":"J Biol Chem"},{"key":"2842_CR6","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.stem.2008.06.002","volume":"3","author":"S Goyama","year":"2008","unstructured":"Goyama S, Yamamoto G, Shimabe M, Sato T, Ichikawa M, Ogawa S, et al. Evi-1 is a critical regulator for hematopoietic stem cells and transformed leukemic cells. Cell Stem Cell. 2008;3:207\u201320.","journal-title":"Cell Stem Cell"},{"key":"2842_CR7","doi-asserted-by":"publisher","first-page":"2403","DOI":"10.1084\/jem.20110447","volume":"208","author":"K Kataoka","year":"2011","unstructured":"Kataoka K, Sato T, Yoshimi A, Goyama S, Tsuruta T, Kobayashi H, et al. Evi1 is essential for hematopoietic stem cell self-renewal, and its expression marks hematopoietic cells with long-term multilineage repopulating activity. J Exp Med. 2011;208:2403\u201316.","journal-title":"J Exp Med"},{"key":"2842_CR8","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1038\/leu.2012.355","volume":"27","author":"OS Kustikova","year":"2013","unstructured":"Kustikova OS, Schwarzer A, Stahlhut M, Brugman MH, Neumann T, Yang M, et al. Activation of Evi1 inhibits cell cycle progression and differentiation of hematopoietic progenitor cells. Leukemia. 2013;27:1127\u201338.","journal-title":"Leukemia"},{"key":"2842_CR9","doi-asserted-by":"publisher","first-page":"e959","DOI":"10.1097\/HS9.0000000000000959","volume":"7","author":"S Lux","year":"2023","unstructured":"Lux S, Milsom MD. EVI1-mediated Programming of Normal and Malignant Hematopoiesis. Hemasphere. 2023;7:e959.","journal-title":"Hemasphere"},{"key":"2842_CR10","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1182\/blood-2009-03-209262","volume":"114","author":"JW Vardiman","year":"2009","unstructured":"Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009;114:937\u201351.","journal-title":"Blood"},{"key":"2842_CR11","doi-asserted-by":"publisher","first-page":"758","DOI":"10.12659\/MSM.905903","volume":"24","author":"YZ Qin","year":"2018","unstructured":"Qin YZ, Zhao T, Zhu HH, Wang J, Jia JS, Lai YY, et al. High EVI1 Expression Predicts Poor Outcomes in Adult Acute Myeloid Leukemia Patients with Intermediate Cytogenetic Risk Receiving Chemotherapy. Med Sci Monit. 2018;24:758\u2013767.","journal-title":"Med Sci Monit"},{"key":"2842_CR12","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1038\/bmt.2016.71","volume":"51","author":"X He","year":"2016","unstructured":"He X, Wang Q, Cen J, Qiu H, Sun A, Chen S, et al. Predictive value of high EVI1 expression in AML patients undergoing myeloablative allogeneic hematopoietic stem cell transplantation in first CR. Bone Marrow Transpl. 2016;51:921\u20137.","journal-title":"Bone Marrow Transpl"},{"key":"2842_CR13","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1038\/leu.2012.211","volume":"27","author":"M Konantz","year":"2013","unstructured":"Konantz M, Andr\u00e9 MC, Ebinger M, Grauer M, Wang H, Grzywna S, et al. EVI-1 modulates leukemogenic potential and apoptosis sensitivity in human acute lymphoblastic leukemia. Leukemia. 2013;27:56\u201365.","journal-title":"Leukemia"},{"key":"2842_CR14","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.yexcr.2018.11.018","volume":"374","author":"W Lang","year":"2019","unstructured":"Lang W, Zhu J, Chen F, Cai J, Zhong J. EVI-1 modulates arsenic trioxide induced apoptosis through JNK signalling pathway in leukemia cells. Exp Cell Res. 2019;374:140\u2013151.","journal-title":"Exp Cell Res"},{"key":"2842_CR15","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1182\/bloodadvances.2022008018","volume":"7","author":"Y Masamoto","year":"2023","unstructured":"Masamoto Y, Chiba A, Mizuno H, Hino T, Hayashida H, Sato T, et al. EVI1 exerts distinct roles in AML via ERG and cyclin D1 promoting a chemoresistant and immune-suppressive environment. Blood Adv. 2023;7:1577\u201393.","journal-title":"Blood Adv"},{"key":"2842_CR16","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/j.cell.2014.02.019","volume":"157","author":"S Gr\u00f6schel","year":"2014","unstructured":"Gr\u00f6schel S, Sanders MA, Hoogenboezem R, de Wit E, Bouwman BAM, Erpelinck C, et al. A single oncogenic enhancer rearrangement causes concomitant EVI1 and GATA2 deregulation in leukemia. Cell. 2014;157:369\u201381.","journal-title":"Cell"},{"key":"2842_CR17","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/j.ccr.2014.02.008","volume":"25","author":"H Yamazaki","year":"2014","unstructured":"Yamazaki H, Suzuki M, Otsuki A, Shimizu R, Bresnick EH, Engel JD, et al. A remote GATA2 hematopoietic enhancer drives leukemogenesis in inv(3)(q21;q26) by activating EVI1 expression. Cancer Cell. 2014;25:415\u201327.","journal-title":"Cancer Cell"},{"key":"2842_CR18","doi-asserted-by":"publisher","first-page":"2868","DOI":"10.1158\/2159-8290.CD-20-1793","volume":"11","author":"L Smeenk","year":"2021","unstructured":"Smeenk L, Ottema S, Mulet-Lazaro R, Ebert A, Havermans M, Varea AA, et al. Selective Requirement of MYB for Oncogenic Hyperactivation of a Translocated Enhancer in Leukemia. Cancer Discov. 2021;11:2868\u201383.","journal-title":"Cancer Discov"},{"key":"2842_CR19","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-021-00457-9","volume":"11","author":"C Birdwell","year":"2021","unstructured":"Birdwell C, Fiskus W, Kadia TM, DiNardo CD, Mill CP, Bhalla KN. EVI1 dysregulation: impact on biology and therapy of myeloid malignancies. Blood Cancer J. 2021;11:64.","journal-title":"Blood Cancer J"},{"key":"2842_CR20","doi-asserted-by":"publisher","first-page":"3127","DOI":"10.1038\/s41375-021-01235-z","volume":"35","author":"S Kiehlmeier","year":"2021","unstructured":"Kiehlmeier S, Rafiee MR, Bakr A, Mika J, Kruse S, M\u00fcller J, et al. Identification of therapeutic targets of the hijacked super-enhancer complex in EVI1-rearranged leukemia. Leukemia. 2021;35:3127\u201338.","journal-title":"Leukemia"},{"key":"2842_CR21","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1038\/s41375-023-02108-3","volume":"38","author":"CE Birdwell","year":"2024","unstructured":"Birdwell CE, Fiskus W, Kadia TM, Mill CP, Sasaki K, Daver N, et al. Preclinical efficacy of targeting epigenetic mechanisms in AML with 3q26 lesions and EVI1 overexpression. Leukemia. 2024;38:545\u201356.","journal-title":"Leukemia"},{"key":"2842_CR22","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.21873\/invivo.12872","volume":"36","author":"DH Albert","year":"2022","unstructured":"Albert DH, Goodwin NC, Davies AM, Rowe J, Feuer G, Boyiadzis M, et al. Co-clinical Modeling of the Activity of the BET Inhibitor Mivebresib (ABBV-075) in AML. In Vivo. 2022;36:1615\u201327.","journal-title":"In Vivo"},{"key":"2842_CR23","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1080\/10428194.2023.2300710","volume":"65","author":"EM Stein","year":"2024","unstructured":"Stein EM, Fathi AT, Harb WA, Colak G, Fusco A, Mangan JK. Results from phase 1 of the MANIFEST clinical trial to evaluate the safety and tolerability of pelabresib in patients with myeloid malignancies. Leuk Lymphoma. 2024;65:503\u201310.","journal-title":"Leuk Lymphoma"},{"key":"2842_CR24","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1182\/blood.2022019306","volume":"145","author":"V Shah","year":"2025","unstructured":"Shah V, Giotopoulos G, Osaki H, Meyerh\u00f6fer M, Meduri E, Gallego-Crespo A, et al. Acute resistance to BET inhibitors remodels compensatory transcriptional programs via p300 coactivation. Blood. 2025;145:748\u201364.","journal-title":"Blood"},{"key":"2842_CR25","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaw0064","volume":"11","author":"GL Lin","year":"2019","unstructured":"Lin GL, Wilson KM, Ceribelli M, Stanton BZ, Woo PJ, Kreimer S, et al. Therapeutic strategies for diffuse midline glioma from high-throughput combination drug screening. Sci Transl Med. 2019;11:eaaw0064.","journal-title":"Sci Transl Med"},{"key":"2842_CR26","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1016\/j.ccell.2021.02.014","volume":"39","author":"A Thomas","year":"2021","unstructured":"Thomas A, Takahashi N, Rajapakse VN, Zhang X, Sun Y, Ceribelli M, et al. Therapeutic targeting of ATR yields durable regressions in small cell lung cancers with high replication stress. Cancer Cell. 2021;39:566\u2013579.e7.","journal-title":"Cancer Cell"},{"key":"2842_CR27","doi-asserted-by":"publisher","first-page":"3617","DOI":"10.1182\/blood-2009-12-261602","volume":"117","author":"A Yoshimi","year":"2011","unstructured":"Yoshimi A, Goyama S, Watanabe-Okochi N, Yoshiki Y, Nannya Y, Nitta E, et al. Evi1 represses PTEN expression and activates PI3K\/AKT\/mTOR via interactions with polycomb proteins. Blood. 2011;117:3617\u201328.","journal-title":"Blood"},{"key":"2842_CR28","doi-asserted-by":"publisher","DOI":"10.1172\/JCI173403","volume":"134","author":"Q Wu","year":"2024","unstructured":"Wu Q, Yu C, Yu F, Guo Y, Sheng Y, Li L, et al. Evi1 governs Kdm6b-mediated histone demethylation to regulate the Laptm4b-driven mTOR pathway in hematopoietic progenitor cells. J Clin Invest. 2024;134:e173403.","journal-title":"J Clin Invest"},{"key":"2842_CR29","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1038\/nrm830","volume":"3","author":"GS Salvesen","year":"2002","unstructured":"Salvesen GS, Duckett CS. IAP proteins: blocking the road to death\u2019s door. Nat Rev Mol Cell Biol. 2002;3:401\u201310.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"2842_CR30","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1038\/onc.2016.310","volume":"36","author":"C Safferthal","year":"2017","unstructured":"Safferthal C, Rohde K, Fulda S. Therapeutic targeting of necroptosis by Smac mimetic bypasses apoptosis resistance in acute myeloid leukemia cells. Oncogene. 2017;36:1487\u2013502.","journal-title":"Oncogene"},{"key":"2842_CR31","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1038\/s43018-021-00177-w","volume":"2","author":"M Hashimoto","year":"2021","unstructured":"Hashimoto M, Saito Y, Nakagawa R, Ogahara I, Takagi S, Takata S, et al. Combined inhibition of XIAP and BCL2 drives maximal therapeutic efficacy in genetically diverse aggressive acute myeloid leukemia. Nat Cancer. 2021;2:340\u201356.","journal-title":"Nat Cancer"},{"key":"2842_CR32","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1016\/j.cell.2013.03.036","volume":"153","author":"J Lov\u00e9n","year":"2013","unstructured":"Lov\u00e9n J, Hoke HA, Lin CY, Lau A, Orlando DA, Vakoc CR, et al. Selective inhibition of tumor oncogenes by disruption of super-enhancers. Cell. 2013;153:320\u201334.","journal-title":"Cell"},{"key":"2842_CR33","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1182\/blood.2019002922","volume":"135","author":"DT Saenz","year":"2020","unstructured":"Saenz DT, Fiskus W, Mill CP, Perera D, Manshouri T, Lara BH, et al. Mechanistic basis and efficacy of targeting the \u03b2-catenin-TCF7L2-JMJD6-c-Myc axis to overcome resistance to BET inhibitors. Blood. 2020;135:1255\u201369.","journal-title":"Blood"},{"key":"2842_CR34","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1016\/j.ccell.2015.05.006","volume":"27","author":"EE Stratikopoulos","year":"2015","unstructured":"Stratikopoulos EE, Dendy M, Szabolcs M, Khaykin AJ, Lefebvre C, Zhou MM, et al. Kinase and BET Inhibitors Together Clamp Inhibition of PI3K Signaling and Overcome Resistance to Therapy. Cancer Cell. 2015;27:837\u201351.","journal-title":"Cancer Cell"},{"key":"2842_CR35","first-page":"2331","volume":"108","author":"G Richard-Carpentier","year":"2023","unstructured":"Richard-Carpentier G, Rausch CR, Sasaki K, Hammond D, Morita K, Takahashi K, et al. Characteristics and clinical outcomes of patients with acute myeloid leukemia with inv(3)(q21q26.2) or t(3;3)(q21;q26.2). Haematologica. 2023;108:2331\u201342.","journal-title":"Haematologica"},{"key":"2842_CR36","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-25862-3","volume":"12","author":"S Ottema","year":"2021","unstructured":"Ottema S, Mulet-Lazaro R, Erpelinck-Verschueren C, van Herk S, Havermans M, Arricibita Varea A, et al. The leukemic oncogene EVI1 hijacks a MYC super-enhancer by CTCF-facilitated loops. Nat Commun. 2021;12:5679.","journal-title":"Nat Commun"}],"updated-by":[{"DOI":"10.1038\/s41375-026-02911-8","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T00:00:00Z","timestamp":1773187200000}}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41375-025-02842-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-025-02842-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-025-02842-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T06:33:36Z","timestamp":1773297216000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-025-02842-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,19]]},"references-count":36,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["2842"],"URL":"https:\/\/doi.org\/10.1038\/s41375-025-02842-w","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,19]]},"assertion":[{"value":"27 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 November 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 December 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 December 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 March 2026","order":6,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":7,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original online version of this article was revised: In the published version of our article, the (-log10 p value) on the y-axis for Figure 1D was calculated and displayed incorrectly. We have corrected the panel to show the properly calculated (-log10 p-value) on the y-axis. The original article has been corrected.","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 March 2026","order":9,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":10,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":11,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1038\/s41375-026-02911-8","URL":"https:\/\/doi.org\/10.1038\/s41375-026-02911-8","order":12,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All authors declare they have no conflict of interests to disclose.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"RNA-Seq datasets have been deposited in GEO under Accession ID GSE297482. The mass spectrometry proteomics data for AML194 cells treated with mivebresib, dactolisib, and LCL161 have been deposited to the ProteomeXchange Consortium via the PRIDE partner repository with dataset identifier PXD063413.\u00a0The compounds utilized and the primary data from the MIPE v5.0 screen have been deposited in PubChem under the following assay ID (AID): 2202231, 2202232, 2202233, 2202234, 2202235, 2202236 and 2202237.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data Sharing"}},{"value":"These studies were conducted in accordance with relevant guidelines and regulations and were approved by the Institutional Review Board of MD Anderson Cancer Center under protocols LAB01-473 and PA16-0468. All samples were collected and tested following approval under these protocols. Informed consent was obtained from all participants. All in vivo studies were approved by the IACUC at M.D. Anderson Cancer Center.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}]}}